Andreas Kaubisch, MD
Medical Oncology · Bronx, NYNPI 1114007606
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,000 of the $17,501 with a category attached, or 97.1%. Janssen Research & Development, LLC accounts for 97.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $9,400 and has fallen 97.5% since, to $231 in 2025.
Across 24 payments — averaging $729.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$17K
- Medtronic$83
- Phadia US Inc.$74
- Ipsen Biopharmaceuticals, Inc$45
- AstraZeneca$43
- Springworks Therapeutics, Inc.$40
- plus $216 from 8 others
Across 69 payments — averaging $6870.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$269K
- AVEO Pharmaceuticals, Inc.$92K
- Eisai Inc.$69K
- Deciphera Pharmaceuticals Inc.$45K
What the payments were for
- Consulting fees$17,00097%
- Food & beverage$4583%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 3 | $17,000 |
| Medtronic | 2 | $83 |
| Phadia US Inc. | 1 | $74 |
| Ipsen Biopharmaceuticals, Inc | 3 | $45 |
| AstraZeneca | 1 | $43 |
| Springworks Therapeutics, Inc. | 2 | $40 |
| Merck | 3 | $39 |
| Tersera Therapeutics LLC | 2 | $38 |
| Novartis | 2 | $36 |
| AbbVie | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
How this compares
$17,501 in reported general payments places this provider in the 65th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Bronx
- Joseph SparanoBronx$125K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
- Ehsan MalekBuffalo$826K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.